Developing approaches to incorporate donor-lung computed tomography images into machine learning models to predict severe primary graft dysfunction after lung transplantation
- PMID: 39924113
- DOI: 10.1016/j.ajt.2025.01.039
Developing approaches to incorporate donor-lung computed tomography images into machine learning models to predict severe primary graft dysfunction after lung transplantation
Abstract
Primary graft dysfunction (PGD) is a common complication after lung transplantation associated with poor outcomes. Although risk factors have been identified, the complex interactions between clinical variables affecting PGD risk are not well understood, which can complicate decisions about donor-lung acceptance. Previously, we developed a machine learning model to predict grade 3 PGD using donor and recipient electronic health record data, but it lacked granular information from donor-lung computed tomography (CT) scans, which are routinely assessed during offer review. In this study, we used a gated approach to determine optimal methods for analyzing donor-lung CT scans among patients receiving first-time, bilateral lung transplants at a single center over 10 years. We assessed 4 computer vision approaches and fused the best with electronic health record data at 3 points in the machine learning process. A total of 160 patients had donor-lung CT scans for analysis. The best imaging-only approach employed a 3D ResNet model, yielding median (interquartile range) areas under the receiver operating characteristic and precision-recall curves of 0.63 (0.49-0.72) and 0.48 (0.35-0.6), respectively. Combining imaging with clinical data using late fusion provided the highest performance, with median areas under the receiver operating characteristic and precision-recall curves of 0.74 (0.59-0.85) and 0.61 (0.47-0.72), respectively.
Keywords: artificial intelligence; computer vision; lung transplantation; machine learning; primary graft dysfunction.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors of this manuscript have conflicts of interest to disclose as described by American Journal of Transplantation. R Hachem sits on the advisory board for Mallinckrodt, the clinical events adjudication committee for Transmedics, and has received grant funding from Bristol Myers Squibb and publication support from Boehringer Ingelheim. AM Lai is a shareholder of Johnson & Johnson. A Sotiras has equity in TheraPanacea and has recieved compensation to review grant for the BrightFocus Foundation. AP Michelson is a shareholder of Pfizer and Viatris. The other authors have no conflicts of interest to disclose as described by American Journal of Transplantation.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
